Details

What is Kevzara (sarilumab) for?

Kevzara (sarilumab) is indicated for the treatment of patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).

How does Kevzara (sarilumab) work?

Kevzara (sarilumab) is a human monoclonal antibody — an interleukin-6 (IL-6) receptor antagonist. IL-6 is a cytokine — a small protein involved in the communication among cells[2]— that, in excess and over time, can contribute to the inflammation associated with rheumatoid arthritis.

Sarilumab binds to the interleukin-6 receptor (IL-6R) and has been shown to inhibit IL-6R mediated signaling.

Where has Kevzara (sarilumab) been approved?

Kevzara (sarilumab) was approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more DMARDs, such as methotrexate (MTX)1 by:

How is Kevzara (sarilumab) taken?

Kevzara (sarilumab) may be used as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs.

The standard dosage is:

Complete information about sarilumab dosage and administration can be found in the references section.

Consult your treating doctor for personalised dosing.

Are there any known side effects of Kevzara (sarilumab)?

Patients treated with Kevzara (sarilumab) are at increased risk of developing serious infections that may lead to hospitalization or death.

The most common adverse reactions (incidence of at least 3%) are:

References

Clinical trials

The approvals were based on 2 randomised, double-blind, placebo-controlled multicentre studies (MOBILITY and TARGET) involving 1,197 and 546 adults.

An important measure in patients with rheumatoid arthritis is the ACR 20, 50 or 70 which is a criteria to measure the improvement of patients of 20%, 50% or 70% based on the following measures: swollen joint count, tender joint count, patient assessment of global status, acute phase reactant (dramatic increase in hepatic synthesis of plasma proteins which accompanies acute phases of tissue injury and inflammation), health professional assessment of global status, physical function, and pain.

Mobility Study

The MOBILITY group of patients had moderately to severely active rheumatoid arthritis and had an inadequate clinical response to methotrexate (MTX). Patients received subcutaneous sarilumab 200 mg, sarilumab 150 mg, or placebo every two weeks with concomitant MTX. After week 16, patients with an inadequate response could have been rescued with sarilumab 200 mg every two weeks.

In the MOBILITY study, treatment with Kevzara plus MTX reduced signs and symptoms, improved physical function, and demonstrated significantly less radiographic progression of structural damage, compared to placebo plus MTX.

At 24 weeks, 66% of the patients treated with Kevzara 200 mg, achieved ACR20, compared with 58% of patients treated with Kevzara 150 mg, and 33% of those on placebo

Target Study

The TARGET group of patients had moderately to severely active rheumatoid arthritis and had an inadequate clinical response or were intolerant to one or more TNF-α antagonists. Patients received subcutaneous sarilumab 200 mg, sarilumab 150 mg, or placebo every two weeks with concomitant conventional DMARD(s) (MTX, sulfasalazine, leflunomide, and/or hydroxychloroquine). After week 12 in Study 2, patients with an inadequate response could have been rescued with sarilumab 200 mg every two weeks.

In the TARGET study, treatment with Kevzara (sarilumab) plus DMARD reduced signs and symptoms and improved physical function, compared to placebo plus DMARD3. At 24 weeks, 61% of patients treated with Kevzara (sarilumab) plus DMARD achieved an ACR20 response, compared with 56% of the patients on sarilumab 150 mg, and 34% of those on placebo.

References

Price & Costs

Kevzara (sarilumab) price in other currencies*

Package	Euro	Australian dollars	Canadian dollar	New Zealand dollar	Nigerian naira	Singapore dollar	Pound sterling	United States dollar
2 prefilled syringes of 150 mg/1.14 mL	1749 EUR	2888 AUD	2610 CAD	3177 NZD	2906330 NGN	2471 SGD	1442 GBP	1842 USD
2 prefilled syringes of 200 mg/1.14 mL	1749 EUR	2888 AUD	2610 CAD	3177 NZD	2906330 NGN	2471 SGD	1442 GBP	1842 USD

*The prices listed above are based on the cheapest package size and strength everyone.org has access to. Please make an enquiry for more specific pricing. The prices listed above are a guide only, we operate in Euros.

Kevzara (sarilumab) treatment costs

The cost for a monthly or yearly treatment of Kevzara (sarilumab) depends on your prescription requirements which includes the dosage in g/mg/ml/etc and medicine type (Prefilled syringe(s)).

The price of the medicines you see on sale is the cost set by the manufacturer. In addition, shipping costs and a Named Patient support fee will apply.

Make an enquiry and we will help you calculate the total price to buy Kevzara (sarilumab) online and have it delivered where you live. From your side, we’ll simply need a prescription from your treating doctor. In some countries we might also need an import license. Our Patient Support team will guide you throughout the process.

Kevzara (sarilumab) price and additional costs

Kevzara (sarilumab) reimbursement

It might be possible for you to claim the cost of Kevzara (sarilumab) via your country's healthcare system. Some countries have a government fund providing financial assistance for citizens to access lifesaving medical treatment abroad. The best thing would be to check with your country's own health ministry. We also highly recommend checking out local patient blogs, communities and patient organisations to find out more about your options.

Medical insurance

Generally, we do not support medical insurance, but we do provide you with an invoice after you make the payment that you may send to your medical insurance company so they can reimburse you. In some limited circumstances, we do accept insurance. Contact us for more details. You can pay by bank transfer or credit card.

Crowdfunding

Crowdfunding might also be an option for you. It is a means of raising funds by using an online platform to group together many small donations from friends, family and others, in order to help you afford medical treatment. Here are some crowdfunding platforms where you can seek support: GoFundMe, GiveForward, FundRazr and Watsi.

Shipping

Cold chain shipping

Some medicinal ingredients are susceptible to damage from heat, light and handling. Using "cold chain" delivery, specialised medical couriers have temperature regulated boxes and vehicles to ensure that the medicine is uncompromised. For that reason, cold chain shipping can be more expensive than regular shipping. For more details, please see our article on cold chain delivery.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order.

Our standard delivery time varies from 5 to 10 working days.

The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

You can also pick up your medicine from our partner pharmacy in Amsterdam or our partner pharmacy in Luxembourg after the order has been paid for.

Our Process

Four steps to access the medicines you need

How and where to access and buy Kevzara: You can access Kevzara from everyone.org if the drug has not been approved or is not available in your country.